Difference between revisions of "Team:Jiangnan"
| Line 156: | Line 156: | ||
</div> | </div> | ||
<div style="position: relative;"> | <div style="position: relative;"> | ||
| − | <img src=" | + | <img src="https://static.igem.org/mediawiki/2018/0/0a/T--Jiangnan--main_top.png" width="100%"> |
<div style="position: absolute;top: 4em;width: 100%;"> | <div style="position: absolute;top: 4em;width: 100%;"> | ||
<div style="text-align: center;"> | <div style="text-align: center;"> | ||
Revision as of 14:11, 17 October 2018
Project Description
The limitingg factors of most vaccine companies, according to our previous invetigation and survey, are
mulitifaceted costs in actual production process and long product lift cycle and other issues due to
to complex application process of new vaccines(call line).
The goal of our project is to enable three features of our chassis cell, i.e.,high titration, suspension cultivation, and
broad spectrum to reduce the production cost increase the yield of viruses for vaccine production. The chassis cell we used here if.
.MDBK cell.
Broad spectrum
Suspension
High titer
Broad spectrum
Through text mining, we classified cell receptors according to the Baltimore subtyping of viruses and summarized the primary receptors mediating the entry of different types of viruses. After systematic analysis, we aim to express Nectin 4 and Tfr on our chassis cells to make them possible to a broad spectrum of viruses.
Suspension
Through high throughput sequencing of two pairs of cells with and without the suspension feature, we found a panel of genes responsible for the suspension feature of cells following network construction using computational approach. The top gene was functionally validated before applied to the chassis cell for genomic modulation.
High titer
Through bioinformatics analysis and mathematical modeling, we constructed the network regulating virus titration of cells. The top gene was selected, functionally validated in vitro and used for genomic modulation in the chassis cells to enable them the feature of increased titration. On the other hand, we manufactured a device to generate cold atmospheric plasma, using which cell titration was further increased in response to plasma irradiation.
